Stockscreener 앱 받기
4.38
2.01%
-0.09
Lantern Pharma Inc 주식(LTRN)의 최신 뉴스
Lantern Pharma Launches AI Tool predictBBB.ai with 94% Accuracy for Blood-Brain Barrier Drug Development - citybuzz -
RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26 - Tri-City Herald
Will Lantern Pharma Inc. price bounce be sustainableJuly 2025 Summary & Safe Capital Preservation Plans - Newser
What does recent volatility data suggest for Lantern Pharma Inc.Market Activity Recap & Accurate Technical Buy Alerts - Newser
Key metrics from Lantern Pharma Inc.’s quarterly data2025 Growth vs Value & Weekly Chart Analysis and Trade Guides - Newser
Is Lantern Pharma Inc. meeting your algorithmic filter criteriaWeekly Stock Recap & High Return Stock Watch Alerts - Newser
Will a bounce in Lantern Pharma Inc. offer an exitTrend Reversal & Daily Technical Forecast Reports - Newser
Can swing trading help recover from Lantern Pharma Inc. lossesTreasury Yields & Smart Investment Allocation Insights - Newser
Published on: 2025-08-17 03:16:20 - Newser
Published on: 2025-08-17 02:12:31 - Newser
What institutional flow reveals about Lantern Pharma Inc.2025 Year in Review & Free Community Consensus Stock Picks - Newser
Analyzing Lantern Pharma Inc. with multi timeframe chartsTrade Volume Report & Verified Entry Point Signals - Newser
Can volume confirm reversal in Lantern Pharma Inc.2025 Fundamental Recap & Capital Protection Trade Alerts - Newser
Price momentum metrics for Lantern Pharma Inc. explainedMarket Movers & Safe Entry Point Alerts - Newser
Applying Wyckoff theory to Lantern Pharma Inc. stockInsider Buying & Free Verified High Yield Trade Plans - Newser
Advanced analytics toolkit walkthrough for Lantern Pharma Inc.2025 Top Decliners & Technical Confirmation Trade Alerts - Newser
Sectors Driving Future Growth for Lantern Pharma Inc. Stock2025 Breakouts & Breakdowns & Safe Entry Zone Tips - Newser
Does Lantern Pharma Inc. have strong EBITDA margins2025 EndofYear Setup & Weekly Hot Stock Watchlists - newsimpact.co.kr
Lantern Pharma secures EU patent for AI-driven cancer drug LP-284 - MSN
Lantern Pharma Inc. Recovery Likely Here’s What Data ShowsJuly 2025 Outlook & Daily Profit Focused Screening - sundaytimes.kr
Lantern Pharma shares fall 6.72% intraday despite positive clinical trial results. - AInvest
What is Lantern Pharma Inc.’s book value per share2025 Analyst Calls & Long Hold Capital Preservation Plans - newsyoung.net
Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses In Multiple Trials - Barchart.com
Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses in Multiple Trials - The Globe and Mail
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates - BioSpace
Lantern Pharma Narrows Loss in Q2 - The Motley Fool
Lantern Pharma Narrows Loss in Q2 - Nasdaq
Lantern Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates | LTRN Stock News - GuruFocus
What data driven models say about Lantern Pharma Inc.’s futureWeekly Trend Watch with Market Signals - Newser
Short Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Rises By 109.5% - MarketBeat
Automated trading signals detected on Lantern Pharma Inc.Free Entry Points For Growing Stocks - Newser
Os Therapies Incorporated shares rise 1.14% intraday after Lantern Pharma's subsidiary cleared IND application for GBM trial. - AInvest
Lantern Pharma Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Lantern Pharma Inc. Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule - citybuzz -
Lantern Pharma (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations - Barchart.com
Lantern Pharma (LTRN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Lantern Pharma Announces Release of Advanced AI Module for Blood-Brain Barrier Permeability Prediction - AI Insider
Nerdy Inc. shares rise 1.78% after-hours following Lantern Pharma's FDA clearance for GBM trial. - AInvest
How Lantern Pharma Inc. stock performs during market volatilityDaily Stock Forecast Powered by AI Tools - Newser
Lantern Pharma (NASDAQ: LTRN) Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial - Barchart.com
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed - openPR.com
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed Clinical Trials And FDA-Approved Therapies Review By Delveinsight Dnatrix, Lantern Pharma, Vyriad, Chimerix, Pfizer, Takeda Pharmaceuticals - Menafn
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | DNAtrix, Lantern Pharma, Vyriad, Chimerix, Pfizer, Takeda Pharmaceuticals - Barchart.com
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial | LTRN Stock News - GuruFocus
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U - GuruFocus
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial - Business Wire
Lantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy - Barchart.com
Lantern Pharma completes Japanese enrolment for lung cancer drug trial - Mugglehead Magazine
Lantern Pharma schließt japanische Rekrutierung für Lungenkrebsmedikamentstudie ab - Mugglehead Magazine
Real Time Chart Alerts Flash Bullish on Lantern Pharma Inc.Swing Trade Plans Emphasize Risk Management - metal.it
Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™ - 01net
Lantern Pharma Announces Public Release of AI Module for Blood-Brain Barrier Permeability Prediction - AInvest
Lantern Pharma Unveils PredictBBB.ai With 94% Accuracy, Revolutionizing CNS Drug Development Through Real-Time AI - 富途牛牛
1.18%
0.54%
자본화:
|
볼륨(24시간):